ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Sep 16, 2024 · CIK: 1715925
Sentiment: neutral
Topics: sec-filing, 6-K, press-release
TL;DR
IPA files 6-K with press release on Sept 16, 2024. Check 20-F for annuals.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on September 16, 2024, to report a press release dated September 16, 2024. The filing indicates the company is a foreign private issuer and will file annual reports under Form 20-F. The press release itself is the primary exhibit, but its specific content is not detailed in this header information.
Why It Matters
This filing serves as an official notification to the SEC and investors about the company's reporting status and includes a press release, which may contain material updates on business operations or financial performance.
Risk Assessment
Risk Level: low — This filing is primarily procedural, indicating the submission of a press release and confirming reporting status, rather than announcing significant financial events or strategic shifts.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Filer of the report
- September 16, 2024 (date) — Date of the press release and filing
- Kristin Taylor (person) — Signatory for the company
- 001-39530 (other) — SEC File Number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report a press release dated September 16, 2024, and to indicate that ImmunoPrecise Antibodies Ltd. files annual reports under Form 20-F.
What is the filing date of this report?
This report was filed on September 16, 2024.
What is the commission file number for ImmunoPrecise Antibodies Ltd.?
The commission file number for ImmunoPrecise Antibodies Ltd. is 001-39530.
What is the primary exhibit included in this filing?
The primary exhibit included in this filing is Exhibit 99.1, a Press Release dated September 16, 2024.
Which form does ImmunoPrecise Antibodies Ltd. use for its annual reports?
ImmunoPrecise Antibodies Ltd. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-09-16 09:03:19
Filing Documents
- earnings_release_sept_16.htm (6-K) — 21KB
- ipa-ex99_1.htm (EX-99.1) — 36KB
- 0000950170-24-106620.txt ( ) — 58KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: September 16, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer